ArticleCardio-oncology (London, England)2025

CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis.

Joshua D Mitchell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.